{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:26:57Z","timestamp":1790018817429,"version":"4.0.1"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008871","name":"Juvenile Diabetes Research Foundation United States of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009238","name":"Virginia Commonwealth University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.addr.2018.12.003","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T22:42:01Z","timestamp":1544136121000},"page":"83-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Advances in immunotherapy of type I diabetes"],"prefix":"10.1016","volume":"139","author":[{"given":"Qianqian","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc B.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson S.","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guizhi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2018.12.003_bb0005","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/nature08933","article-title":"Genetics, pathogenesis and clinical interventions in type 1 diabetes","volume":"464","author":"Bluestone","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.addr.2018.12.003_bb0010","doi-asserted-by":"crossref","first-page":"17016","DOI":"10.1038\/nrdp.2017.16","article-title":"Type 1 diabetes mellitus","volume":"3","author":"Katsarou","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.addr.2018.12.003_bb0015","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"Dimeglio","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2018.12.003_bb0020","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s12020-016-1033-3","article-title":"Antigen-based immunotherapies do not prevent progression of recent-onset autoimmune diabetes: a systematic review and meta-analysis","volume":"54","author":"Rizava","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.addr.2018.12.003_bb0025","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nrendo.2012.237","article-title":"Immune therapy in type 1 diabetes mellitus","volume":"9","author":"Lernmark","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.addr.2018.12.003_bb0030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006103","article-title":"Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8(+) T cells in type 1 diabetes","volume":"5","author":"Roep","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2018.12.003_bb0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1107096","article-title":"GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus","volume":"366","author":"Ludvigsson","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.12.003_bb0040","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.2337\/db14-1693","article-title":"Detection of antibodies directed to the N-terminal region of GAD is dependent on assay format and contributes to differences in the specificity of GAD autoantibody assays for type 1 diabetes","volume":"64","author":"Williams","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2018.12.003_bb0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s13317-015-0068-4","article-title":"Anti-zinc transporter protein 8 autoantibodies significantly improve the diagnostic approach to type 1 diabetes: an Italian multicentre study on paediatric patients","volume":"6","author":"Fabris","year":"2015","journal-title":"Auto Immun. Highlights"},{"key":"10.1016\/j.addr.2018.12.003_bb0050","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8848","article-title":"A divergent population of autoantigen-responsive CD4(+) T cells in infants prior to beta cell autoimmunity","volume":"9","author":"Heninger","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2018.12.003_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2006.03244.x","article-title":"Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes","volume":"148","author":"Di Lorenzo","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0060","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1172\/JCI72271","article-title":"Molecular mechanisms of diabetic kidney disease","volume":"124","author":"Reidy","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2018.12.003_bb0065","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.kint.2017.04.018","article-title":"Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy","volume":"92","author":"Galsgaard","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2018.12.003_bb0070","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3389\/fimmu.2018.00392","article-title":"Peptide immunotherapy for type 1 diabetes-clinical advances","volume":"9","author":"Smith","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/ITT.S117264","article-title":"Targeting innate immunity to downmodulate adaptive immunity and reverse type 1 diabetes","volume":"6","author":"Itoh","year":"2017","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.addr.2018.12.003_bb0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11892-017-0863-6","article-title":"Cell therapy for type 1 diabetes: current and future strategies","volume":"17","author":"Aghazadeh","year":"2017","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.addr.2018.12.003_bb0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.addr.2017.05.013","article-title":"Combinatorial drug delivery approaches for immunomodulation","volume":"114","author":"Stewart","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2018.12.003_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2015.07.006","article-title":"Nanotherapeutics for autoimmunity becomes mainstream","volume":"160","author":"Giannoukakis","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0095","first-page":"493","article-title":"Glucocorticoids and diabetes mellitus","volume":"52","author":"Vondra","year":"2006","journal-title":"Vnitr. Lek."},{"key":"10.1016\/j.addr.2018.12.003_bb0100","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.wem.2014.09.033","article-title":"Diabetic ketoacidosis and acute mountain sickness: case report and review of treatment options in type 1 diabetes mellitus","volume":"26","author":"Miller","year":"2015","journal-title":"Wilderness Environ. Med."},{"key":"10.1016\/j.addr.2018.12.003_bb0105","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.4049\/jimmunol.168.7.3635","article-title":"Human DQ8 can substitute for murine I-Ag7 in the selection of diabetogenic T cells restricted to I-Ag7","volume":"168","author":"Wen","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0923-2494(97)87237-9","article-title":"Insights into the chemistry and biology of the I-Ag7 class II molecule","volume":"148","author":"Carrasco-Marin","year":"1997","journal-title":"Res. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0115","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1126\/science.1972595","article-title":"Autoimmune diseases: the failure of self tolerance","volume":"248","author":"Sinha","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.addr.2018.12.003_bb0120","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1172\/JCI22103","article-title":"Prevention of type 1 diabetes by gene therapy","volume":"114","author":"Tian","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2018.12.003_bb0125","doi-asserted-by":"crossref","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2018.12.003_bb0130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1126\/science.aaa7017","article-title":"Immune tolerance. Regulatory T cells generated early in life play a distinct role in maintaining self-tolerance","volume":"348","author":"Yang","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.addr.2018.12.003_bb0135","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MOT.0000000000000566","article-title":"Taking regulatory T-cell therapy one step further","volume":"23","author":"Sicard","year":"2018","journal-title":"Curr. Opin. Organ Transplant."},{"key":"10.1016\/j.addr.2018.12.003_bb0140","first-page":"488","article-title":"Treatment of metastatic melanoma: an overview","volume":"23","author":"Bhatia","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.addr.2018.12.003_bb0145","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.clim.2013.02.005","article-title":"IL-2 therapy in type 1 diabetes: \"Trials\" and tribulations","volume":"149","author":"Long","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0150","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","article-title":"Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1DM patients","volume":"58","author":"Rosenzwajg","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.addr.2018.12.003_bb0155","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.2337\/db12-0049","article-title":"Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function","volume":"61","author":"Long","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2018.12.003_bb0160","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.2337\/db15-0516","article-title":"Natural variation in interleukin-2 sensitivity influences regulatory T-cell frequency and function in individuals with long-standing type 1 diabetes","volume":"64","author":"Yang","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2018.12.003_bb0165","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1073\/pnas.91.1.123","article-title":"Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice","volume":"91","author":"Chatenoud","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2018.12.003_bb0170","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/imt-2016-0049","article-title":"Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside","volume":"8","author":"Kuhn","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.addr.2018.12.003_bb0175","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.12.003_bb0180","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","article-title":"A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes","volume":"54","author":"Herold","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2018.12.003_bb0185","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.2337\/dc13-0327","article-title":"Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes","volume":"37","author":"Aronson","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2018.12.003_bb0190","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nri2134","article-title":"CD3-specific antibodies: a portal to the treatment of autoimmunity","volume":"7","author":"Chatenoud","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0195","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/imm.12729","article-title":"Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity","volume":"151","author":"Wallberg","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2018.12.003_bb0200","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1016\/j.febslet.2011.04.025","article-title":"Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity","volume":"585","author":"Chen","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2018.12.003_bb0205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"H. intensive care in, G. oncological patients collaborative, new drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.addr.2018.12.003_bb0210","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.it.2011.03.006","article-title":"B cell-directed therapies in type 1 diabetes","volume":"32","author":"Marino","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0215","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"C.D.S.G. type 1 diabetes trialNet Anti, Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.12.003_bb0220","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-065X.2010.00945.x","article-title":"B-cell targeted therapies in human autoimmune diseases: an updated perspective","volume":"237","author":"Townsend","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.addr.2018.12.003_bb0225","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrd3402","article-title":"Immunomodulatory therapy to preserve pancreatic beta-cell function in type 1 diabetes","volume":"10","author":"Waldron-Lynch","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2018.12.003_bb0230","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clim.2013.02.003","article-title":"Anti-cytokine therapies in T1DM: concepts and strategies","volume":"149","author":"Nepom","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0235","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygeno.2013.12.007","article-title":"Temporal profiling of cytokine-induced genes in pancreatic beta-cells by meta-analysis and network inference","volume":"103","author":"Lopes","year":"2014","journal-title":"Genomics"},{"key":"10.1016\/j.addr.2018.12.003_bb0240","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.phrs.2014.07.004","article-title":"The rise, fall, and resurgence of immunotherapy in type 1 diabetes","volume":"98","author":"Ben Nasr","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.addr.2018.12.003_bb0245","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/eji.201546005","article-title":"G. type 1 diabetes trialNet Canakinumab study, T. Mandrup-Poulsen, A.S. Group, M.J. Hessner, Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset","volume":"46","author":"Cabrera","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0250","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard.2004.033662","article-title":"Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice","volume":"65","author":"den Broeder","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.addr.2018.12.003_bb0255","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nrendo.2009.271","article-title":"Blockade of interleukin 1 in type 1 diabetes mellitus","volume":"6","author":"Mandrup-Poulsen","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.addr.2018.12.003_bb0260","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1399-5448.2011.00761.x","article-title":"Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes","volume":"12","author":"Sumpter","year":"2011","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.addr.2018.12.003_bb0265","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2337\/dc09-0054","article-title":"Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study","volume":"32","author":"Mastrandrea","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2018.12.003_bb0270","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","article-title":"Type 1 diabetes","volume":"383","author":"Atkinson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2018.12.003_bb0275","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/MED.0b013e32835edb89","article-title":"Revisiting the notion of type 1 diabetes being a T-cell-mediated autoimmune disease","volume":"20","author":"Skog","year":"2013","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.addr.2018.12.003_bb0280","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/imm.12867","article-title":"Harnessing the power of regulatory T-cells to control autoimmune diabetes: overview and perspective","volume":"153","author":"Yu","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2018.12.003_bb0285","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2249.2008.03860.x","article-title":"Analysis of islet inflammation in human type 1 diabetes","volume":"155","author":"Willcox","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0290","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1900\/RDS.2012.9.68","article-title":"Immunotherapy in autoimmune type 1 diabetes","volume":"9","author":"Weigmann","year":"2012","journal-title":"Rev. Diabet. Stud."},{"key":"10.1016\/j.addr.2018.12.003_bb0295","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0300","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1126\/science.1183021","article-title":"Regulation of adaptive immunity by the innate immune system","volume":"327","author":"Iwasaki","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.addr.2018.12.003_bb0305","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri2138","article-title":"Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans","volume":"7","author":"Roncarolo","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0310","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1681\/ASN.2006101143","article-title":"Regulatory T cells and T cell depletion: role of immunosuppressive drugs","volume":"18","author":"Noris","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2018.12.003_bb0315","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1172\/JCI37865","article-title":"Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD\/SCID recipient mice","volume":"119","author":"Bending","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2018.12.003_bb0320","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.clinbiochem.2015.05.019","article-title":"Mechanisms of immunological tolerance","volume":"49","author":"Waldmann","year":"2016","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.addr.2018.12.003_bb0325","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10439-014-1125-2","article-title":"Strategies to direct the enrichment, expansion, and recruitment of regulatory cells for the treatment of disease","volume":"43","author":"Glowacki","year":"2015","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.addr.2018.12.003_bb0330","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.addr.2018.12.003_bb0335","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nri2889","article-title":"Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases","volume":"10","author":"Buckner","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0340","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.immuni.2012.03.020","article-title":"Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency","volume":"36","author":"Bettini","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2018.12.003_bb0345","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mam.2014.12.004","article-title":"Immunogenetics of type 1 diabetes mellitus","volume":"42","author":"Morran","year":"2015","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.addr.2018.12.003_bb0350","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.4049\/jimmunol.1600255","article-title":"The Clonal invariant NKT cell Repertoire in people with type 1 diabetes is characterized by a loss of Clones expressing high-affinity TCRs","volume":"198","author":"Tocheva","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0355","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2337\/db11-1746","article-title":"Autoantigen-specific B-cell depletion overcomes failed immune tolerance in type 1 diabetes","volume":"61","author":"Henry","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2018.12.003_bb0360","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri2153","article-title":"Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease","volume":"7","author":"Miller","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0365","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.addr.2017.04.005","article-title":"In vivo reprogramming of immune cells: technologies for induction of antigen-specific tolerance","volume":"114","author":"Pearson","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2018.12.003_bb0370","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nature16962","article-title":"Expanding antigen-specific regulatory networks to treat autoimmunity","volume":"530","author":"Clemente-Casares","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.addr.2018.12.003_bb0375","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cmet.2017.09.016","article-title":"Antigen-specific peptide immunotherapy for type 1 diabetes: proof of safety, hope for efficacy","volume":"26","author":"Coppieters","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.addr.2018.12.003_bb0380","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.intimp.2010.07.008","article-title":"Immunotherapy of type 1 diabetes--how to rationally prioritize combination therapies in T1DM","volume":"10","author":"Boettler","year":"2010","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.addr.2018.12.003_bb0385","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1172\/JCI24758","article-title":"Genetic epidemiology of diabetes","volume":"115","author":"Permutt","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2018.12.003_bb0390","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrg3069","article-title":"Understanding type 1 diabetes through genetics: advances and prospects","volume":"12","author":"Polychronakos","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2018.12.003_bb0395","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.smim.2011.07.003","article-title":"Immune intervention in type 1 diabetes","volume":"23","author":"Michels","year":"2011","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0400","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2249.2008.03814.x","article-title":"Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study","volume":"155","author":"Thrower","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0405","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf7779","article-title":"Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes","volume":"9","author":"Alhadj Ali","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2018.12.003_bb0410","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(11)60895-7","article-title":"G.A.D.S.G. Type 1 diabetes trialNet, antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial","volume":"378","author":"Wherrett","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2018.12.003_bb0415","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2337\/dc13-2359","article-title":"T. type 1 diabetes, G. diabetes prevention trial-type 1 study, use of the diabetes prevention trial-type 1 risk score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes","volume":"37","author":"Sosenko","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2018.12.003_bb0420","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/JIM.0000000000000227","article-title":"Immune interventions to preserve beta cell function in type 1 diabetes","volume":"64","author":"Ehlers","year":"2016","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.addr.2018.12.003_bb0425","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/acs.bioconjchem.5b00625","article-title":"Stable Evans blue derived exendin-4 peptide for type 2 diabetes treatment","volume":"27","author":"Liu","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2018.12.003_bb0430","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/s41467-017-01764-1","article-title":"Microneedle-array patches loaded with dual mineralized protein\/peptide particles for type 2 diabetes therapy","volume":"8","author":"Chen","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2018.12.003_bb0435","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/vaccines3030662","article-title":"Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy","volume":"3","author":"Fan","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2018.12.003_bb0440","doi-asserted-by":"crossref","first-page":"11109","DOI":"10.1021\/acs.chemrev.5b00109","article-title":"Synthetic nanoparticles for vaccines and immunotherapy","volume":"115","author":"Irvine","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2018.12.003_bb0445","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.coi.2011.10.001","article-title":"Diabetogenic T lymphocytes in human type 1 diabetes","volume":"23","author":"Roep","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0450","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jaut.2017.12.010","article-title":"Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells","volume":"89","author":"Prasad","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.addr.2018.12.003_bb0455","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clim.2015.03.004","article-title":"Generation of antigen-specific Foxp3+ regulatory T-cells in vivo following administration of diabetes-reversing tolerogenic microspheres does not require provision of antigen in the formulation","volume":"160","author":"Engman","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0460","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clim.2015.03.023","article-title":"A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabetic NOD mice","volume":"160","author":"Lewis","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.addr.2018.12.003_bb0465","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jconrel.2015.12.040","article-title":"Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes","volume":"223","author":"Zhao","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.12.003_bb0470","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jconrel.2011.08.009","article-title":"Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival","volume":"156","author":"Dane","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.12.003_bb0475","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.addr.2017.06.007","article-title":"Bioengineering strategies for inducing tolerance in autoimmune diabetes","volume":"114","author":"Baekkeskov","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2018.12.003_bb0480","doi-asserted-by":"crossref","first-page":"ra61","DOI":"10.1126\/scisignal.aad0612","article-title":"Tolerogenic nanoparticles inhibit T cell-mediated autoimmunity through SOCS2","volume":"9","author":"Yeste","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.addr.2018.12.003_bb0485","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2337\/db16-0946","article-title":"In vivo enrichment of diabetogenic T cells","volume":"66","author":"Thelin","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2018.12.003_bb0490","doi-asserted-by":"crossref","first-page":"13155","DOI":"10.1038\/srep13155","article-title":"A combination hydrogel microparticle-based vaccine prevents type 1 diabetes in non-obese diabetic mice","volume":"5","author":"Yoon","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2018.12.003_bb0495","doi-asserted-by":"crossref","first-page":"148rv149","DOI":"10.1126\/scitranslmed.3003763","article-title":"Engineering approaches to immunotherapy","volume":"4","author":"Swartz","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2018.12.003_bb0500","doi-asserted-by":"crossref","first-page":"869718","DOI":"10.1155\/2013\/869718","article-title":"Targeting antigens to dendritic cell receptors for vaccine development","volume":"2013","author":"Apostolopoulos","year":"2013","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.addr.2018.12.003_bb0505","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1084\/jem.20021598","article-title":"Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance","volume":"196","author":"Bonifaz","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.addr.2018.12.003_bb0510","doi-asserted-by":"crossref","first-page":"232ra251","DOI":"10.1126\/scitranslmed.3008068","article-title":"Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205","volume":"6","author":"Dhodapkar","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2018.12.003_bb0515","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1900\/RDS.2012.9.305","article-title":"Targeted antigen delivery to DEC-205(+) dendritic cells for tolerogenic vaccination","volume":"9","author":"Petzold","year":"2012","journal-title":"Rev. Diabet. Stud."},{"key":"10.1016\/j.addr.2018.12.003_bb0520","doi-asserted-by":"crossref","first-page":"9311","DOI":"10.1073\/pnas.96.16.9311","article-title":"Prevalent CD8(+) T cell response against one peptide\/MHC complex in autoimmune diabetes","volume":"96","author":"Anderson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2018.12.003_bb0525","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.immuni.2010.03.015","article-title":"Reversal of autoimmunity by boosting memory-like autoregulatory T cells","volume":"32","author":"Tsai","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2018.12.003_bb0530","doi-asserted-by":"crossref","first-page":"12176","DOI":"10.18632\/oncotarget.7519","article-title":"A biodegradable killer microparticle to selectively deplete antigen-specific T cells in vitro and in vivo","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X18303065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X18303065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:46:08Z","timestamp":1759207568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X18303065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":106,"alternative-id":["S0169409X18303065"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2018.12.003","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in immunotherapy of type I diabetes","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2018.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}